A clinical trial update dated May 4, 2026 reports on a study involving cetrorelix, a GnRH antagonist. The trial, registered as NCT06212102, is titled "Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation." The study is listed as Phase 2 and its current status is recruiting.
According to the registration, the trial is designed to compare dydrogesterone against a GnRH antagonist regimen, which includes cetrorelix, in patients classified as poor responders undergoing double ovarian stimulation. No results have been posted for this trial as of the listed date, and no outcome data are available in the event record.
This update reflects only the trial's registration status and design as recorded on ClinicalTrials.gov. It does not indicate any findings, efficacy signals, or safety conclusions regarding cetrorelix or dydrogesterone. Readers interested in the study's progress should monitor the official registry listing for future updates, including any changes in recruitment status or eventual results postings.
For general background on this compound, see the compound overview.